Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 12 | 2025 | 672 | 2.490 |
Why?
|
| Erectile Dysfunction | 2 | 2021 | 22 | 1.520 |
Why?
|
| Analgesics, Opioid | 4 | 2025 | 509 | 1.370 |
Why?
|
| Hypoglycemia | 2 | 2017 | 68 | 1.040 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 211 | 0.950 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 86 | 0.940 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 677 | 0.880 |
Why?
|
| Pregnancy in Adolescence | 2 | 2013 | 23 | 0.840 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 37 | 0.830 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2021 | 6 | 0.760 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 144 | 0.710 |
Why?
|
| Depression, Postpartum | 3 | 2023 | 162 | 0.700 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 276 | 0.690 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6140 | 0.660 |
Why?
|
| Hypertension | 2 | 2022 | 603 | 0.650 |
Why?
|
| Pregnancy Outcome | 3 | 2023 | 189 | 0.600 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 538 | 0.580 |
Why?
|
| United States | 14 | 2025 | 7622 | 0.580 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 201 | 0.580 |
Why?
|
| Electronic Health Records | 2 | 2021 | 354 | 0.570 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 25 | 0.570 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 14 | 0.570 |
Why?
|
| Weight Gain | 1 | 2017 | 163 | 0.520 |
Why?
|
| Pain | 4 | 2023 | 406 | 0.480 |
Why?
|
| Blood Glucose | 2 | 2018 | 475 | 0.480 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 5197 | 0.440 |
Why?
|
| Delirium | 2 | 2025 | 62 | 0.430 |
Why?
|
| Humans | 28 | 2025 | 60142 | 0.430 |
Why?
|
| Pregnancy, Unwanted | 1 | 2012 | 10 | 0.420 |
Why?
|
| Female | 21 | 2025 | 31253 | 0.410 |
Why?
|
| Risk Assessment | 3 | 2016 | 1937 | 0.410 |
Why?
|
| Pregnancy, Unplanned | 1 | 2012 | 22 | 0.410 |
Why?
|
| Algorithms | 2 | 2022 | 1002 | 0.400 |
Why?
|
| Intention | 1 | 2012 | 66 | 0.400 |
Why?
|
| Male | 16 | 2025 | 27975 | 0.390 |
Why?
|
| Pregnancy | 8 | 2023 | 2367 | 0.380 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 2505 | 0.380 |
Why?
|
| Aged | 13 | 2025 | 13584 | 0.380 |
Why?
|
| Tretinoin | 1 | 2011 | 49 | 0.370 |
Why?
|
| Pain Management | 2 | 2024 | 152 | 0.360 |
Why?
|
| Behavioral Symptoms | 2 | 2021 | 16 | 0.360 |
Why?
|
| Prevalence | 5 | 2023 | 1300 | 0.360 |
Why?
|
| Carcinoma | 1 | 2011 | 117 | 0.350 |
Why?
|
| Mothers | 1 | 2013 | 269 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 832 | 0.330 |
Why?
|
| Cohort Studies | 4 | 2023 | 2480 | 0.310 |
Why?
|
| Premature Birth | 2 | 2022 | 108 | 0.290 |
Why?
|
| Infant, Newborn | 5 | 2023 | 1315 | 0.280 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 405 | 0.260 |
Why?
|
| Skin Ulcer | 1 | 2025 | 14 | 0.240 |
Why?
|
| Social Participation | 1 | 2025 | 16 | 0.240 |
Why?
|
| Young Adult | 6 | 2024 | 4396 | 0.240 |
Why?
|
| Adult | 7 | 2024 | 15988 | 0.230 |
Why?
|
| Delayed-Action Preparations | 1 | 2025 | 111 | 0.230 |
Why?
|
| Risk Factors | 4 | 2023 | 5083 | 0.220 |
Why?
|
| Fractures, Bone | 1 | 2025 | 150 | 0.220 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2023 | 11 | 0.210 |
Why?
|
| Suppuration | 1 | 2023 | 11 | 0.210 |
Why?
|
| Accidental Falls | 1 | 2025 | 154 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 807 | 0.210 |
Why?
|
| Ulcer | 1 | 2023 | 15 | 0.210 |
Why?
|
| Arthritis, Psoriatic | 1 | 2023 | 32 | 0.210 |
Why?
|
| Rhode Island | 2 | 2013 | 99 | 0.210 |
Why?
|
| Pain Measurement | 2 | 2021 | 337 | 0.210 |
Why?
|
| Spondylarthritis | 1 | 2023 | 42 | 0.200 |
Why?
|
| Perinatal Death | 1 | 2022 | 5 | 0.200 |
Why?
|
| Tadalafil | 1 | 2021 | 2 | 0.200 |
Why?
|
| Carbolines | 1 | 2021 | 8 | 0.190 |
Why?
|
| Drug Utilization | 2 | 2021 | 223 | 0.190 |
Why?
|
| Prescription Drug Misuse | 1 | 2022 | 22 | 0.190 |
Why?
|
| Chronic Pain | 1 | 2024 | 145 | 0.190 |
Why?
|
| Neuralgia | 1 | 2021 | 21 | 0.190 |
Why?
|
| Nitrates | 1 | 2021 | 20 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 214 | 0.190 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2022 | 51 | 0.180 |
Why?
|
| Prenatal Care | 2 | 2013 | 180 | 0.180 |
Why?
|
| Depressive Disorder | 1 | 2023 | 292 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5263 | 0.180 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 792 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2020 | 40 | 0.170 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 173 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 122 | 0.170 |
Why?
|
| Homes for the Aged | 1 | 2021 | 164 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 301 | 0.160 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2023 | 325 | 0.160 |
Why?
|
| Logistic Models | 2 | 2013 | 1259 | 0.160 |
Why?
|
| Anticonvulsants | 1 | 2020 | 95 | 0.160 |
Why?
|
| Middle Aged | 6 | 2025 | 16539 | 0.160 |
Why?
|
| Epilepsy | 1 | 2020 | 111 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 190 | 0.150 |
Why?
|
| Medicare | 4 | 2023 | 603 | 0.140 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 35 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 63 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2021 | 489 | 0.140 |
Why?
|
| Immunization | 1 | 2016 | 130 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 33 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 2616 | 0.120 |
Why?
|
| Vaccines | 1 | 2016 | 97 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 691 | 0.120 |
Why?
|
| Adolescent | 3 | 2018 | 5957 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 2362 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 719 | 0.110 |
Why?
|
| Time Factors | 2 | 2024 | 3619 | 0.110 |
Why?
|
| Heart Failure | 1 | 2021 | 869 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1265 | 0.110 |
Why?
|
| Insulin | 1 | 2018 | 689 | 0.110 |
Why?
|
| Maternal Age | 1 | 2013 | 34 | 0.110 |
Why?
|
| Maternal Behavior | 1 | 2013 | 31 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 1592 | 0.100 |
Why?
|
| Family Planning Services | 1 | 2012 | 21 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1471 | 0.100 |
Why?
|
| Biomarkers | 1 | 2017 | 1213 | 0.100 |
Why?
|
| Risk-Taking | 1 | 2012 | 159 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2011 | 52 | 0.090 |
Why?
|
| Keratinocytes | 1 | 2011 | 63 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 189 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 366 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1035 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 392 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2011 | 681 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1525 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1565 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 517 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 1098 | 0.070 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 100 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2023 | 99 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 95 | 0.050 |
Why?
|
| Perinatal Care | 1 | 2023 | 61 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2023 | 387 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 19 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2023 | 161 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2021 | 34 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 969 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 67 | 0.050 |
Why?
|
| Analgesics | 1 | 2021 | 101 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 849 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 15 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2020 | 35 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 774 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2021 | 219 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 71 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 892 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 281 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 868 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 51 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 158 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 2015 | 26 | 0.030 |
Why?
|
| Data Collection | 1 | 2016 | 383 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1140 | 0.030 |
Why?
|
| Child | 1 | 2023 | 4335 | 0.030 |
Why?
|